The revised guidelines also will lead to more than $20 million in extra health care costs, the research shows.
The decision by the Center for Disease Control and Prevention to stop recommending giving infants a dose of the hepatitis B ...
The FDA has accepted for Priority Review the New Drug Application for bepirovirsen for the treatment of adults with chronic hepatitis B.
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. The Trump ...
HBV reactivation risk rises after rituximab in CHB patients post-antiviral withdrawal. Learn more about relapse timing and ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has ...
CNW/ - GSK today announced that it has filed a new drug submission for bepirovirsen for regulatory review in Canada.
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 ...
Hosted on MSN
FDA grants priority review for GSK hepatitis B drug
The US FDA has granted priority review to GSK's bepirovirsen, an antisense oligonucleotide therapy for chronic hepatitis B licensed from Ionis Pharmaceuticals. Supported by positive Phase 3 trial ...
The World Health Organization has issued its first-ever hepatitis B guidelines that outline how to determine who needs treatment, what medicines to use and how to monitor patients long-term. The ...
The World Health Organization (WHO) released a new report on hepatitis today, marking the World Hepatitis Summit. Since 2015, ...
According to the WHO’s 2026 Global Hepatitis Report, the decline reflects sustained global efforts, though viral hepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results